GlassScriptPhysician profile
Keiko Sawano
NPI 1114369881
$7,989.10
in general payments reported to CMS, 2019-2025
43 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,186 · 2022: $1,475 · 2023: $3,499 · 2024: $1,340 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,398 · Travel and Lodging: $1,640 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,397.53 |
| Travel and Lodging | $1,640.21 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200.00 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,584.11 | 2023 | Vns Therapy |
| Inspire Medical Systems, INC. | $1,114.93 | 2023-2025 | Inspire |
| Abbvie INC. | $949.56 | 2021-2024 | |
| Genzyme Corporation | $680.97 | 2021-2024 | |
| Jazz Pharmaceuticals INC. | $500.52 | 2021-2025 | |
| Ucb, INC. | $430.20 | 2021-2024 | Briviact, Nayzilam |
| Novartis Pharmaceuticals Corporation | $352.77 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $196.93 | 2021-2023 | Ponvory |
| Biogen, INC. | $196.32 | 2021-2023 | Spinraza |
| Biohaven Pharmaceutical Holding Company LTD. | $189.02 | 2022 | |
| Sk Life Science, INC. | $154.68 | 2022-2024 | |
| Celgene Corporation | $154.52 | 2023-2024 | Zeposia |
| Kyowa Kirin, INC. | $142.39 | 2021-2023 | Nourianz |
| Sunovion Pharmaceuticals INC. | $124.83 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $122.78 | 2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keiko Sawano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.